Procyon develops test for prostate cancer staging
This article was originally published in Clinica
Executive Summary
The Canadian biopharmaceutical company, Procyon BioPharma, is developing a protein marker test for prostate cancer which it claims could help doctors assess the stage of the disease more accurately than current methods on the market.